AI Can Now Coach Amateur Virologists, and Top Tech Leaders Want Congress to Act on DNA Security

Why It Matters

Mandatory DNA‑order screening would close a critical biosecurity gap, reducing the risk that AI‑enhanced actors could synthesize harmful pathogens.

Key Takeaways

• AI now outperforms PhDs on virology lab‑procedure queries
• Tech leaders demand legal DNA‑order screening and traceability
• Voluntary screening exists, but uniform rules are lacking
• Screening is low‑cost, effective, and enjoys rare cross‑industry consensus

Pulse Analysis

The synthesis of DNA fragments has become a routine service for research labs, but the technology also enables the rapid assembly of pathogenic viruses. For two decades scientists have warned that synthetic DNA could be misused, yet enforcement has relied on voluntary screening by providers. Recent advances in artificial intelligence have amplified the concern: AI models can now answer detailed virology protocol questions with accuracy that surpasses many trained researchers, effectively eroding the knowledge barrier that once protected against bioweapon development.

Against this backdrop, a coalition of top tech executives and leading scientists published an open letter to the U.S. Congress, calling for a statutory requirement that all synthetic DNA orders be screened for dual‑use risk. The signatories include CEOs of major cloud and biotech firms, as well as prominent academic virologists. They argue that screening is the most effective, least restrictive safeguard available and that uniform rules—paired with mandatory record‑keeping—would create a traceable supply chain, making it harder for bad actors to obtain dangerous sequences undetected.

If Congress adopts the proposed legislation, the biotech supply chain could see standardized compliance protocols, similar to existing export‑control regimes for chemicals. Companies would need to implement automated screening software and retain detailed transaction logs, potentially increasing operational costs modestly but delivering substantial risk reduction. Moreover, the move could set a global precedent, encouraging other nations to adopt comparable standards and fostering international collaboration on biosecurity. As AI continues to accelerate scientific discovery, aligning regulatory frameworks with emerging capabilities will be essential to safeguard public health while preserving innovation.